Payment overview · 2025
General Payments
$824.79
49 reported records · 17 companies
Healthcare provider profile · identity verified
Jonathan Eric Marston, MD
Allopathic & Osteopathic Physicians|Family Medicine · FARMVILLE, VA · NPI 1841376720
Verified facts
What the public records show
CMS Open Payments records show Jonathan Eric Marston, MD received $824.79 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $268.94 | 32.6% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.67 | 17.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.39 | 6.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.13 | 5.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.62 | 5.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.14 | 4.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.80 | 4.5% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.45 | 3.0% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $22.34 | 2.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.40 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.43 | 2.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.41 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.95 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.19 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.53 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.59 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $824.79 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $188.77 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $185.56 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.64 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.17 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.39 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.39 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.90 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.74 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.03 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.03 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.03 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 228 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1186 | 226 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 212 |
| Losartan Potassium | Losartan Potassium | 845 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 786 | 151 |
| Hydrochlorothiazide | Hydrochlorothiazide | 582 | 134 |
| Omeprazole | Omeprazole | 556 | 117 |
| Potassium Chloride | Potassium Chloride | 519 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 498 | 99 |
| Metformin Hcl Er | Metformin Hcl | 475 | 126 |
| Ezetimibe | Ezetimibe | 447 | 81 |
| Lisinopril | Lisinopril | 441 | 100 |
| Alprazolam | Alprazolam | 371 | 68 |
| Gabapentin | Gabapentin | 359 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 319 | 70 |
| Tramadol Hcl | Tramadol Hcl | 306 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 71 |
| Furosemide | Furosemide | 303 | 79 |
| Lovastatin | Lovastatin | 280 | 59 |
| Simvastatin | Simvastatin | 242 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 56 |
| Metformin Hcl | Metformin Hcl | 239 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 51 |
| Lorazepam | Lorazepam | 229 | 32 |
| Eliquis | Apixaban | 228 | 49 |
| Glimepiride | Glimepiride | 220 | 48 |
| Sertraline Hcl | Sertraline Hcl | 220 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 181 | 37 |
| Prednisone | Prednisone | 180 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 35 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 173 | 28 |
| Famotidine | Famotidine | 172 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 61 |
| Tradjenta | Linagliptin | 149 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 144 | suppressed |
| Ozempic | Semaglutide | 142 | 20 |
| Spironolactone | Spironolactone | 139 | 30 |
| Carvedilol | Carvedilol | 136 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 34 |
| Jardiance | Empagliflozin | 127 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 24 |
| Januvia | Sitagliptin Phosphate | 115 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 20 |
| Farxiga | Dapagliflozin Propanediol | 108 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 106 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 20 |
| Trazodone Hcl | Trazodone Hcl | 104 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 101 | 52 |
| Allopurinol | Allopurinol | 100 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 26 |
| Montelukast Sodium | Montelukast Sodium | 96 | 28 |
| Xarelto | Rivaroxaban | 96 | 14 |
| Atenolol | Atenolol | 94 | 19 |
| Ketoconazole | Ketoconazole | 94 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 57 |
| Alendronate Sodium | Alendronate Sodium | 84 | 21 |
| Cefuroxime | Cefuroxime Axetil | 84 | 63 |
| Clonazepam | Clonazepam | 76 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 14 |
| Warfarin Sodium | Warfarin Sodium | 71 | 13 |
| Diazepam | Diazepam | 69 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 15 |
| Donepezil Hcl | Donepezil Hcl | 67 | 11 |
| Amoxicillin | Amoxicillin | 66 | 50 |
| Azithromycin | Azithromycin | 65 | 49 |
| Mirtazapine | Mirtazapine | 63 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 60 | 13 |
| Colchicine | Colchicine | 59 | 21 |
| Mupirocin | Mupirocin | 59 | 38 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | suppressed |
| Meloxicam | Meloxicam | 58 | suppressed |
| Pregabalin | Pregabalin | 58 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 16 |
| Novolog Flexpen | Insulin Aspart | 57 | 12 |
| Glyxambi | Empagliflozin/Linagliptin | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 49 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Sucralfate | Sucralfate | 42 | 15 |
| Finasteride | Finasteride | 41 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 15 |
| Ondansetron Odt | Ondansetron | 40 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 29 |
| Baclofen | Baclofen | 37 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alprazolam Xr | Alprazolam | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Fluocinonide | Fluocinonide | 22 | 14 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $824.79 · 49 records | ABBVIE INC. | ABRYSVO, AREXVY, BEXSERO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Kerendia, MOUNJARO, NEXPLANON, NURTEC ODT, OPSUMIT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, SUBLOCADE, UBRELVY, UPTRAVI, VRAYLAR, Wegovy, Yeztugo, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error